Pursue Wealth Partners LLC Makes New $226,000 Investment in Ascendis Pharma A/S (NASDAQ:ASND)

Pursue Wealth Partners LLC acquired a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 1,451 shares of the biotechnology company's stock, valued at approximately $226,000.

Several other hedge funds also recently added to or reduced their stakes in the stock. RA Capital Management L.P. grew its holdings in Ascendis Pharma A/S by 4.1% during the 4th quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company's stock worth $1,392,221,000 after acquiring an additional 402,316 shares in the last quarter. Avoro Capital Advisors LLC grew its holdings in Ascendis Pharma A/S by 2.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 5,103,055 shares of the biotechnology company's stock worth $702,538,000 after acquiring an additional 114,167 shares in the last quarter. Artisan Partners Limited Partnership grew its holdings in Ascendis Pharma A/S by 0.9% during the 4th quarter. Artisan Partners Limited Partnership now owns 4,450,420 shares of the biotechnology company's stock worth $612,689,000 after acquiring an additional 39,309 shares in the last quarter. Janus Henderson Group PLC lifted its position in shares of Ascendis Pharma A/S by 4.6% in the 4th quarter. Janus Henderson Group PLC now owns 4,380,382 shares of the biotechnology company's stock worth $602,910,000 after buying an additional 193,688 shares during the last quarter. Finally, Capital International Investors lifted its position in shares of Ascendis Pharma A/S by 35.7% in the 4th quarter. Capital International Investors now owns 2,863,249 shares of the biotechnology company's stock worth $394,183,000 after buying an additional 753,859 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on ASND shares. JPMorgan Chase & Co. raised their price target on shares of Ascendis Pharma A/S from $200.00 to $245.00 and gave the stock an "overweight" rating in a research report on Friday, May 2nd. Morgan Stanley upgraded shares of Ascendis Pharma A/S from an "equal weight" rating to an "overweight" rating and raised their price target for the stock from $180.00 to $250.00 in a research report on Monday, May 5th. Royal Bank Of Canada raised their price target on shares of Ascendis Pharma A/S from $205.00 to $210.00 and gave the stock an "outperform" rating in a research report on Friday, May 2nd. Oppenheimer restated an "outperform" rating and issued a $224.00 price target (up from $215.00) on shares of Ascendis Pharma A/S in a research report on Friday, June 13th. Finally, Bank of America raised their price target on shares of Ascendis Pharma A/S from $201.00 to $216.00 and gave the stock a "buy" rating in a research report on Monday, June 9th. One research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $220.67.

Ascendis Pharma A/S Trading Down 0.0%

NASDAQ:ASND traded down $0.05 during mid-day trading on Thursday, hitting $172.95. The stock had a trading volume of 353,316 shares, compared to its average volume of 496,737. The stock has a market capitalization of $10.57 billion, a price-to-earnings ratio of -27.54 and a beta of 0.37. The company has a 50 day simple moving average of $166.28 and a 200-day simple moving average of $150.51. Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $183.00.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The company had revenue of $123.97 million for the quarter, compared to analysts' expectations of $98.56 million. As a group, equities research analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.